

Moxifloxacin (Avelox[®])

No. 69/03

Bayer

Summary of Recommendation

13 October, 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for restricted use within NHS Scotland

REASONS FOR ADVICE

Moxifloxacin (Avelox[®]), a new fluoroquinolone antibiotic, should be reserved as a second line treatment for community acquired pneumonia in accordance with British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) guidance.

Professor D H Lawson
Chairman